Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Seong-Joon | - |
dc.contributor.author | Lee, Jin Soo | - |
dc.contributor.author | Choi, Mun Hee | - |
dc.contributor.author | Lee, Sung Eun | - |
dc.contributor.author | Shin, Dong Hoon | - |
dc.contributor.author | Hong, Ji Man | - |
dc.date.available | 2020-02-27T17:43:41Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2017-08-29 | - |
dc.identifier.issn | 1471-2377 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/5827 | - |
dc.description.abstract | Background: In order to evaluate the impact of cilostazol on endothelial function, we compared the changes of flow-mediated dilation (FMD) between aspirin and cilostazol groups in patients with acute cerebral ischemia. Methods: Patients presenting with acute cerebral ischemic events were randomly assigned into aspirin (n = 40) or cilostazol (n = 40) group in a double-blinded manner. FMD was measured at baseline (T0) and 90 days (T1). We measured L-arginine at baseline (a precursor of biologically active nitric oxides). Serious and non-serious adverse events were described. Results: Despite no difference in the baseline FMD values (p = 0.363), there was a significant increase of FMD values in cilostazol group (7.9 +/- 2.4 to 8.9 +/- 2.3%, p = 0.001) and not in aspirin group (8.5 +/- 2.6 to 9.3 +/- 2.8%, p = 0.108). In the multiple regression analysis performed in cilostazol group, serum L-arginine levels were inversely correlated with FMD at T1 (beta = -0.050, SE: 0.012, p < 0.001) with age, total cholesterol levels, and C-reactive protein as confounders. While T0 FMD values in both aspirin and cilostazol groups did not show any correlation with serum L-arginine levels, the correlation is restored in the cilostazol group at T1 (r = 0.467, p = 0.007), while such is not shown in the aspirin group. There was no difference of serious adverse events between the two groups (p = 0.235). Adverse events were more common in the cilostazol group (35/40 vs. 25/40, p = 0.010), due to frequent headaches (14/40 vs. 3/30, p = 0.003) which was well tolerated. Conclusion: Cilostazol improved endothelial function in acute cerebral ischemia patients. It also restored an inverse correlation between 3-month FMD and baseline L-arginine levels. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BIOMED CENTRAL LTD | - |
dc.relation.isPartOf | BMC NEUROLOGY | - |
dc.subject | CAMP-PHOSPHODIESTERASE INHIBITOR | - |
dc.subject | TYPE-2 DIABETES-MELLITUS | - |
dc.subject | VASCULAR SMOOTH-MUSCLE | - |
dc.subject | L-ARGININE | - |
dc.subject | ASYMMETRIC DIMETHYLARGININE | - |
dc.subject | ESSENTIAL-HYPERTENSION | - |
dc.subject | DYSFUNCTION | - |
dc.subject | ATHEROSCLEROSIS | - |
dc.subject | STROKE | - |
dc.subject | VASODILATION | - |
dc.title | Cilostazol improves endothelial function in acute cerebral ischemia patients: a double-blind placebo controlled trial with flow-mediated dilation technique | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000408724700004 | - |
dc.identifier.doi | 10.1186/s12883-017-0950-y | - |
dc.identifier.bibliographicCitation | BMC NEUROLOGY, v.17 | - |
dc.identifier.scopusid | 2-s2.0-85028450577 | - |
dc.citation.title | BMC NEUROLOGY | - |
dc.citation.volume | 17 | - |
dc.contributor.affiliatedAuthor | Shin, Dong Hoon | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Endothelium | - |
dc.subject.keywordAuthor | Cilostazol | - |
dc.subject.keywordAuthor | Cerebral infarction | - |
dc.subject.keywordAuthor | Transient ischemic attack | - |
dc.subject.keywordAuthor | Arginine | - |
dc.subject.keywordPlus | CAMP-PHOSPHODIESTERASE INHIBITOR | - |
dc.subject.keywordPlus | TYPE-2 DIABETES-MELLITUS | - |
dc.subject.keywordPlus | VASCULAR SMOOTH-MUSCLE | - |
dc.subject.keywordPlus | L-ARGININE | - |
dc.subject.keywordPlus | ASYMMETRIC DIMETHYLARGININE | - |
dc.subject.keywordPlus | ESSENTIAL-HYPERTENSION | - |
dc.subject.keywordPlus | DYSFUNCTION | - |
dc.subject.keywordPlus | ATHEROSCLEROSIS | - |
dc.subject.keywordPlus | STROKE | - |
dc.subject.keywordPlus | VASODILATION | - |
dc.relation.journalResearchArea | Neurosciences & Neurology | - |
dc.relation.journalWebOfScienceCategory | Clinical Neurology | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.